Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Terns Pharmaceuticals ( (TERN) ).
On June 11, 2025, Terns Pharmaceuticals held its Annual Meeting of Stockholders where two key proposals were voted on. The election of three Class I directors was approved, and Ernst & Young LLP was ratified as the independent public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (TERN) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Terns Pharmaceuticals stock, see the TERN Stock Forecast page.
Spark’s Take on TERN Stock
According to Spark, TipRanks’ AI Analyst, TERN is a Neutral.
Terns Pharmaceuticals’ overall score reflects significant financial challenges due to lack of revenue and ongoing losses. Despite strong cash reserves and low debt, the company faces high risk due to persistent cash burn. The stock’s technical indicators suggest a bearish trend, and its negative valuation factors further hinder attractiveness. However, the new CFO appointment could enhance strategic financial management, offering a glimmer of potential improvement.
To see Spark’s full report on TERN stock, click here.
More about Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies for the treatment of liver diseases and cancer.
Average Trading Volume: 1,012,970
Technical Sentiment Signal: Hold
Current Market Cap: $338.9M
See more data about TERN stock on TipRanks’ Stock Analysis page.